GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (LTS:0SGC) » Definitions » Cyclically Adjusted Revenue per Share

Arbutus Biopharma (LTS:0SGC) Cyclically Adjusted Revenue per Share : $0.21 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Arbutus Biopharma Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arbutus Biopharma's adjusted revenue per share for the three months ended in Sep. 2024 was $0.007. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.21 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Arbutus Biopharma's average Cyclically Adjusted Revenue Growth Rate was -36.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -22.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -22.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Arbutus Biopharma was -12.50% per year. The lowest was -23.00% per year. And the median was -17.70% per year.

As of today (2024-12-14), Arbutus Biopharma's current stock price is $3.5488. Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2024 was $0.21. Arbutus Biopharma's Cyclically Adjusted PS Ratio of today is 16.90.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arbutus Biopharma was 19.76. The lowest was 1.02. And the median was 5.37.


Arbutus Biopharma Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Arbutus Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Cyclically Adjusted Revenue per Share Chart

Arbutus Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.46 0.42 0.27

Arbutus Biopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.33 0.27 0.25 0.24 0.21

Competitive Comparison of Arbutus Biopharma's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PS Ratio falls into.



Arbutus Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arbutus Biopharma's adjusted Revenue per Share data for the three months ended in Sep. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.007/133.0289*133.0289
=0.007

Current CPI (Sep. 2024) = 133.0289.

Arbutus Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201412 0.195 99.070 0.262
201503 0.155 99.621 0.207
201506 0.063 100.684 0.083
201509 0.080 100.392 0.106
201512 0.217 99.792 0.289
201603 0.012 100.470 0.016
201606 0.006 101.688 0.008
201609 0.014 101.861 0.018
201612 -0.004 101.863 -0.005
201703 0.004 102.862 0.005
201706 0.019 103.349 0.024
201709 0.126 104.136 0.161
201712 0.046 104.011 0.059
201803 0.026 105.290 0.033
201806 0.022 106.317 0.028
201809 0.029 106.507 0.036
201812 0.030 105.998 0.038
201903 0.012 107.251 0.015
201906 0.011 108.070 0.014
201909 0.054 108.329 0.066
201912 0.027 108.420 0.033
202003 0.022 108.902 0.027
202006 0.022 108.767 0.027
202009 0.019 109.815 0.023
202012 0.028 109.897 0.034
202103 0.023 111.754 0.027
202106 0.024 114.631 0.028
202109 0.033 115.734 0.038
202112 0.024 117.630 0.027
202203 0.085 121.301 0.093
202206 0.096 125.017 0.102
202209 0.039 125.227 0.041
202212 0.040 125.222 0.042
202303 0.041 127.348 0.043
202306 0.028 128.729 0.029
202309 0.028 129.860 0.029
202312 0.013 129.419 0.013
202403 0.009 131.776 0.009
202406 0.009 132.554 0.009
202409 0.007 133.029 0.007

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Arbutus Biopharma  (LTS:0SGC) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arbutus Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.5488/0.21
=16.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arbutus Biopharma was 19.76. The lowest was 1.02. And the median was 5.37.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arbutus Biopharma Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Arbutus Biopharma Business Description

Industry
Traded in Other Exchanges
Address
701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.

Arbutus Biopharma Headlines

No Headlines